Spotlight On... UT Southwestern team creates new drug that could aid in vaccine development; GSK seeks to expand FluLaval indication; China FDA clears Sinovac to start producing EV71 vaccine; and more...

Researchers at the University of Texas Southwestern Medical Center have discovered a new drug that could help in vaccine development. It activates the innate immune system in a novel way, UT Southwestern said in a statement. "The drug we made appears safe, and boosts immunity in mice. Therefore, the drug, which is straightforward to synthesize and to couple to antigens that induce an immune response, may prove useful in the generation of vaccines," said Dr. Bruce Beutler, Director of UT Southwestern's Center for the Genetics of Host Defense. More

> GlaxoSmithKline ($GSK) filed a regulatory submission in the U.S. to expand the indication of its FluLaval Quadrivalent vaccine. Release

> The China FDA issued a GMP certificate to Sinovac ($SVA), clearing it to start producing a vaccine for EV71, which causes hand, foot and mouth disease. More

> Mymetics announced it will discontinue its RSV collaborative project in July. Release

And Finally... Drexel University researchers found that 75% of vaccine-related posts on Pinterest are negative toward vaccination. Release

Suggested Articles

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.